Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8691479rdf:typepubmed:Citationlld:pubmed
pubmed-article:8691479lifeskim:mentionsumls-concept:C0379900lld:lifeskim
pubmed-article:8691479lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:8691479lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:8691479lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:8691479pubmed:issue7lld:pubmed
pubmed-article:8691479pubmed:dateCreated1996-8-26lld:pubmed
pubmed-article:8691479pubmed:abstractTextTwelve N,N-dipropyl-substituted derivatives of trans-2-arylcyclopropylamine have been prepared and assayed for their ability to displace [(3)H]-8-OH-DPAT from rat brain 5-HT(1A) receptors. The new derivatives include phenyl (7a), bromo- (7b) and fluorophenyl (7c-e), 2-methoxy-5-fluorophenyl (7h), and 2-hydroxy-5-fluorophenyl (7l) as well as trifluoromethylphenyl (7f) and 2,3-dichlorophenyl (7g) analogues. In the present series of compounds, electron-withdrawing substituents in the phenyl ring appear to decrease the affinity for 5-HT(1A) receptors. In contrast, electron-rich aryl groups, such as 2- or 3-thienyl (7j and 7k, respectively), provide compounds with high affinity. The additional bulk produced by the aromatic moiety in the 2-benzothienyl derivative 7i appears to be detrimental to 5-HT(1A) receptor affinity. The racemic mixtures of the interesting 7j and 7l were resolved into the enantiomers; 7j and 7l exhibited a high enantiomeric 5-HT(1A) receptor affinity ratio (75-fold and 100-fold, respectively). The enantiomers of 7j and 7l were evaluated in vivo by use of biochemical and behavioral tests in rats. Compound (1R,2R)-7j behaved as a partial agonist whereas (1R,2S)-7l appeared as an efficacious 5-HT(1A) receptor agonist, stimulating both autoreceptors and postsynaptic receptors.lld:pubmed
pubmed-article:8691479pubmed:languageenglld:pubmed
pubmed-article:8691479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:citationSubsetIMlld:pubmed
pubmed-article:8691479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691479pubmed:statusMEDLINElld:pubmed
pubmed-article:8691479pubmed:monthMarlld:pubmed
pubmed-article:8691479pubmed:issn0022-2623lld:pubmed
pubmed-article:8691479pubmed:authorpubmed-author:HjorthSSlld:pubmed
pubmed-article:8691479pubmed:authorpubmed-author:HacksellUUlld:pubmed
pubmed-article:8691479pubmed:authorpubmed-author:SvenssonB EBElld:pubmed
pubmed-article:8691479pubmed:authorpubmed-author:ArvidssonL...lld:pubmed
pubmed-article:8691479pubmed:authorpubmed-author:VallgårdaJJlld:pubmed
pubmed-article:8691479pubmed:authorpubmed-author:AppelbergUUlld:pubmed
pubmed-article:8691479pubmed:issnTypePrintlld:pubmed
pubmed-article:8691479pubmed:day29lld:pubmed
pubmed-article:8691479pubmed:volume39lld:pubmed
pubmed-article:8691479pubmed:ownerNLMlld:pubmed
pubmed-article:8691479pubmed:authorsCompleteYlld:pubmed
pubmed-article:8691479pubmed:pagination1485-93lld:pubmed
pubmed-article:8691479pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:meshHeadingpubmed-meshheading:8691479-...lld:pubmed
pubmed-article:8691479pubmed:year1996lld:pubmed
pubmed-article:8691479pubmed:articleTitletrans-2-Aryl-N,N-dipropylcyclopropylamines: synthesis and interactions with 5-HT(1A) receptors.lld:pubmed
pubmed-article:8691479pubmed:affiliationDepartment of Organic Pharmaceutical Chemistry, Uppsala Biomedical Center, Uppsala University, Uppsala, Sweden.lld:pubmed
pubmed-article:8691479pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8691479pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:8691479lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8691479lld:pubmed